+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Systemic Lupus Erythematosus Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • ID: 4997420
  • Report
  • January 2022
  • Region: Global
  • 120 Pages
  • Mordor Intelligence


  • Eli Lilly & Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline
  • ImmuPharma PLC
  • Mylan AG
  • Novartis AG

The systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease which affects multiple organs with a wide variety of clinical manifestations. The past decades, have observed growth in the use of corticosteroids and conventional immunosuppressive drugs, however, the unmet need of drugs with better efficacy and safety profile is still there. The major traction to this market is continuous involvement of big biopharmaceutical companies into drugs presently in clinical trials, which boost the growth of this market. In addition, the burden of growing autoimmune diseases also fuels the growth of the Systemic Lupus Erythematosus market. As per the Lupus Foundation of America, the year 2019 observed growth of several companies such as GSK, and Aurinia Pharmaceuticals Inc, for the lupus treatment. Therefore, the forecast period, is expected to showcase good growth rate in the Systemic Lupus Erythematosus market. However, the cost restraint and stringent regulatory guidelines for new drugs are expected to be among the primary hindrances.

Key Market Trends

Treatment via Biologics is Expected to Witness Better Growth Over the Forecast Period

  • Because of the heterogenous nature of the disease, there is a growing demand at the patients and hospitals end as well as manufacturers for the development of biological treatments which modulates various aspects of the immune responses.
  • The recent years have seen growth of several companies in biological drugs into clinical trials and market approval, which boost the growth of this segment. Since several biologics are in the later stage of the development, the growth is expected to be better over the forecast period.
  • As per the 2018 funded study by the Lupus Foundation of America, the females in their teen and adult life are major sufferers of this disease and was among the top 20 leading cause of death among females. Such facts, raises the concerns regarding approval of drugs which are more target disease specific, therefore, the role of biologic in the treatment of SLE is inevitable over the forecast period.

North America is Expected to Hold a Significant Share in the Market with Similar Trend in the Forecast Period

North America is expected to hold a major market share in the global Systemic Lupus Erythematosus market owing to increased awareness about the disease in the society, better healthcare infrastructure, and growing number of foundations and independent venture groups supporting the biopharmaceutical manufacturers. Several companies have released several general awareness programs regarding the diagnosis, misconceptions and treatment of the disease across the North American region. This is primarily boosted by the many non-profit organisations and funding communities supporting the cause. Nearly 1.5 million people in America have some form of lupus, where 70% contribution is from the SLE form, and more than 90% diagnosed patients are women in their teenage and adult life. Several supportive factors, from government and private sectors as well as funding towards drugs developments, boost the demand of this market in the region and therefore, it is expected to be major market across geographies, over the forecast period.

Competitive Landscape

With wide range of cortecosteroids and immunosuppressants already present in the market, there is growing focus on collaborative drug development programs among the global players as well as new players in the particular geographic region. Many drugs in clinical trials, also attracts several funding partners and manufacturers to head for market approval in the forecast period. Some of the major companies in this segment include GlaxoSmithKline, Eli Lilly & Company, Mylan AG, F. Hoffmann-La Roche AG, Sanofi SA, and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Eli Lilly & Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline
  • ImmuPharma PLC
  • Mylan AG
  • Novartis AG

1.1 Study Assumptions
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Autoimmune Diseases
4.2.2 Medical Advacements by Biopharmaceutical Companies in SLE
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Several Misconceptions and Social Stigmas
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Treatment Type
5.1.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
5.1.2 Antimalarials
5.1.3 Corticosteroids
5.1.4 Biologics
5.1.5 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Intravenous
5.2.3 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 GlaxoSmithKline
6.1.2 F. Hoffmann-La Roche AG
6.1.3 Pfizer Limited
6.1.4 Sanofi SA
6.1.5 Eli Lilly & Company
6.1.6 Mylan AG
6.1.7 Novartis AG
6.1.8 ImmuPharma PLC
6.1.9 Bristl Myers Squibb Company
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • GlaxoSmithKline
  • F. Hoffmann-La Roche AG
  • Pfizer Limited
  • Sanofi SA
  • Eli Lilly & Company
  • Mylan AG
  • Novartis AG
  • ImmuPharma PLC
  • Bristl Myers Squibb Company
Note: Product cover images may vary from those shown